Publications
Detailed Information
Tumor specificity and in vivo targeting of an antibody against exon 9 deleted E-cadherin in gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyuk-Joon | - |
dc.contributor.author | Lee, Hye Seung | - |
dc.contributor.author | Hur, Keun | - |
dc.contributor.author | Kim, Woo Ho | - |
dc.contributor.author | Yanagihara, Kazuyoshi | - |
dc.contributor.author | Becker, Karl-Friedrich | - |
dc.contributor.author | Lee, Kuhn Uk | - |
dc.contributor.author | Yang, Han-Kwang | - |
dc.date.accessioned | 2009-09-20T09:07:06Z | - |
dc.date.available | 2009-09-20T09:07:06Z | - |
dc.date.issued | 2007-06-20 | - |
dc.identifier.citation | J Cancer Res Clin Oncol 133:987-994 | en |
dc.identifier.issn | 0171-5216 (print) | - |
dc.identifier.issn | 1432-1335 (online) | - |
dc.identifier.uri | https://hdl.handle.net/10371/9668 | - |
dc.description.abstract | Purpose The aim of this study was to evaluate the possibility of using a monoclonal antibody against exon 9 deleted E-cadherin (E-cad delta 9-1) for immunotherapy of gastric cancer.
Methods Among nine human diffuse-type gastric cancer cell lines, we selected a cell line expressing exon 9 deleted E-cadherin (HSC-45M2) by direct sequencing. Tumor specificity and tumor specific in vivo targeting of E-cad delta 9-1 were evaluated in nude mouse bearing a tumor derived from HSC-45M2 cell line by immunohistochemical staining. The expression rate of E-cad delta 9-1 was evaluated in 299 gastric cancer patients, and in positive cases, the mutational status of E-cadherin exon 9 was examined. Results Immunohistochemical staining of various tissues from nude mice showed that only tumor tissue reacted with E-cad delta 9-1. However, immunohistochemical staining of the same tissues after systemic injection of E-cad delta 9-1 showed that reticuloendothelial and hypervascular organs reacted with E-cad delta 9-1, but tumor tissue showed only a slight reaction. Evaluation of the reactivity of 299 gastric cancer patients to E-cad delta 9-1 showed that 4.8% (9/187) of patients, who all had diffuse- or mixed-type gastric cancers, reacted positively, but none of the 112 intestinal-type gastric cancer patients reacted positively. Two of 9 patients (22%) with positive staining to E-cad delta 9-1 were confirmed to have mutant forms of E-cadherin exon 9. Conclusion Considering that E-cad delta 9-1 showed good tumor specificity and that some diffuse-type gastric cancers were immunopositive to it, this antibody could be a candidate therapeutic antibody against gastric cancers that express mutant E-cadherin. | en |
dc.description.sponsorship | This study was supported by grant no. 04-2004-
036 from the Seoul National University Hospital Research Fund. | en |
dc.language.iso | en | - |
dc.publisher | Springer Verlag | en |
dc.subject | E-cadherin | en |
dc.subject | Exon 9 | en |
dc.subject | Mutation | en |
dc.subject | Monoclonal antibody | en |
dc.subject | Immunotherapy | en |
dc.subject | Gastric cancer | en |
dc.title | Tumor specificity and in vivo targeting of an antibody against exon 9 deleted E-cadherin in gastric cancer | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 이혁준 | - |
dc.contributor.AlternativeAuthor | 이혜승 | - |
dc.contributor.AlternativeAuthor | 허근 | - |
dc.contributor.AlternativeAuthor | 김우호 | - |
dc.contributor.AlternativeAuthor | 이건욱 | - |
dc.contributor.AlternativeAuthor | 양한광 | - |
dc.identifier.doi | 10.1007/s00432-007-0246-5 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.